Yervoy-Nivolumab Combination Treatment Shrinks Tumors 80 Percent in Three Months
Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint
Trial Shows Standard-Dose Radiotherapy Safer, More Effective than Higher Doses
Vaccine Increases PFS 146%, OS 60% In Phase II Clinical Trial
Cediranib Demonstates Control In Alveolar Soft Part Sarcoma
Antibody Targeting PD-L1 Shows Fast Tumor Shrinkage
Shared Decisionmaking Called For In PSA Screening For Ages 55-69
ACCP Publishes Guidelines Recommending Low-Dose CT
Study: Routine CT Not Needed In Detecting DLBCL Remissions
Surveillance Following Surgery Sufficient in Stage I Seminoma
Fitness Reduces Risk of Death From Lung, Colorectal, Prostate Cancer in Middle-Aged Men
NCI CTEP Approved Trials For the Month of May
FDA Approves Bayer’s Xofigo For Late-Stage Prostate Cancer
Trending Stories
- Preparing to take care of each other in ways we never imagined
- 20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect
- From the chairs of ECOG-ACRIN: A perspective on indirect costs
- On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns”
